Verapamil Hydrochloride Injection, USP 10 mg/4 mL (2.5 mg/mL), 5 x 4 mL Single-Dose Vial per cart...
FDA Drug Recall #D-0593-2024 — Class III — July 2, 2024
Recall Summary
| Recall Number | D-0593-2024 |
| Classification | Class III — Low risk |
| Date Initiated | July 2, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Zydus Pharmaceuticals (USA) Inc |
| Location | Pennington, NJ |
| Product Type | Drugs |
| Quantity | 8020 vials |
Product Description
Verapamil Hydrochloride Injection, USP 10 mg/4 mL (2.5 mg/mL), 5 x 4 mL Single-Dose Vial per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Vadodara, India, Distributed by: Zydus Pharmaceuticals (USA)Inc., Pennington, NJ 08534, Vial NDC: 70710-1644-1, Carton NDC: 70710-1644-5.
Reason for Recall
Cross contamination with other products.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot L300269, Exp Date 07/31/2025
Other Recalls from Zydus Pharmaceuticals (USA) Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0544-2026 | Class II | Erythromycin Tablets, USP, 250 mg, 30 tablets p... | Apr 29, 2026 |
| D-0545-2026 | Class II | Erythromycin Tablets, USP, 500 mg, 30 tablets p... | Apr 29, 2026 |
| D-0400-2026 | Class II | Icosapent Ethyl Capsules, 1 gram, 120 Capsules ... | Mar 9, 2026 |
| D-0295-2026 | Class II | Icosapent Ethyl capsules, 1 gram, 120-count bot... | Dec 30, 2025 |
| D-0247-2026 | Class III | traZODONE Hydrochloride Tablets, USP, 100mg, 1,... | Dec 19, 2025 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.